23 May ViroCell Biologics
Driven by innovation and built around one of the most prolific academic viral vector manufacturing teams, ViroCell Biologics is focused on supporting therapeutic developers using lentiviral and retroviral vectors from the earliest stages of vector design & optimization through preclinical supply to clinical GMP manufacturing. We are committed to helping companies improve safety and solve the next challenges in cell and gene therapy through our innovation research programs. Our team leverages its deep track record in vector design and innovation to help clients de-risk their products with data-driven vector selection to move to the clinic with confidence. ViroCell’s platform processes and established capabilities enable clients to accelerate their novel therapies into GMP manufacturing and release so that they can reach the clinic quickly and affordably. ViroCell’s MHRA-licensed facility is in London, from which we export globally. Our clients come from all over the world and range from academic investigators to large pharma.
